Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study

BACKGROUND: Camptothecin (CPT) and its derivatives are currently used as second- or third-line treatment for patients with endocrine-resistant breast cancer (BC). These drugs convert nuclear enzyme DNA topoisomerase I (TOP1) to a cell poison with the potential to damage DNA by increasing the half-li...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Tesauro, Cinzia, Simonsen, Anne Katrine, Andersen, Marie Bech, Petersen, Kamilla Wandsoe, Kristoffersen, Emil Laust, Algreen, Line, Hansen, Noriko Yokoyama, Andersen, Anne Bech, Jakobsen, Ann Katrine, Stougaard, Magnus, Gromov, Pavel, Knudsen, Birgitta R., Gromova, Irina
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6884793/
https://ncbi.nlm.nih.gov/pubmed/31783818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6371-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires